Amgen Expands Oncology Portfolio with Up to $840M Acquisition of Dark Blue Therapeutics
Dark Blue Therapeutics' lead asset is a small-molecule degrader of MLLT1 and MLLT3 proteins currently being tested in acute myeloid leukemia (AML). This acquisition is part of Amgen's strategic push into innovative cancer therapies in the hematology space.
Deal Highlights
- Amgen is acquiring Dark Blue Therapeutics in a deal worth as much as $840 million.
- The focus is on Dark Blue’s small-molecule degrader targeting MLLT1 and MLLT3, proteins involved in AML.
Strategic Rationale
- The acquisition complements Amgen’s existing oncology pipeline.
- It reinforces commitment to developing targeted degraders that can improve outcomes in difficult-to-treat leukemias.
Clinical Context
- AML remains a challenging cancer with high unmet medical need.
- Small-molecule degraders represent a novel therapeutic modality with potential advantages over traditional inhibitors.
Source: BioSpace
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.